{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:43:08Z","timestamp":1776260588468,"version":"3.50.1"},"reference-count":49,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: Myelodysplastic syndromes (MDS) are associated with a significant risk of progression to acute myeloid leukemia (AML), affecting approximately 30% of patients. In high-risk MDS, leukemic transformation may occur within a short time frame, highlighting the need for early and reliable biomarkers of disease progression. Increasing evidence suggests that immune dysregulation and cytotoxic T-cell dysfunction contribute to disease evolution. This study aimed to evaluate PD-1 and CD57 expressions on CD8+ T cells and to investigate the CD8+PD-1+\/CD4+PD-1+ ratio (PERLS) as a potential immunological marker predictive of leukemic transformation. Methods: Thirty-one patients with MDS were prospectively followed over a 12-month period. At baseline, patients underwent routine clinical and laboratory evaluation, including multiparameter flow cytometric assessment of bone marrow blasts. An extended immunophenotypic analysis of bone marrow samples was performed at study entry to assess PD-1 and CD57 expression on CD8+ T cells. Cytogenetic and molecular analyses were conducted when clinical findings suggested disease progression. Patients who developed signs of progression were re-evaluated approximately one month later, during the progression phase, to assess dynamic immunological changes. Results: Of the thirty-one patients included, eighteen progressed to AML, whereas thirteen remained clinically stable. Patients who progressed demonstrated a significant increase in PD-1 and CD57 expression on CD8+ T cells compared with stable patients. Moreover, a markedly higher CD8+PD-1+\/CD4+PD-1+ (PERLS) ratio was observed in patients who subsequently developed AML, particularly during the progression phase. Conclusions: Dynamic immunophenotypic monitoring reveals that increased PD-1 on CD8+ T cells and an elevated PERLS ratio are associated with imminent leukemic transformation in MDS. These findings support the incorporation of immune-based biomarkers, particularly the CD8+PD-1+\/CD4+PD-1+ ratio, into routine risk assessment to enable earlier identification of disease progression and timely therapeutic intervention.<\/jats:p>","DOI":"10.3390\/hematolrep18020029","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:25:30Z","timestamp":1776255930000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Prognostic Value of the CD8+PD-1+\/CD4+PD-1+ (PERLS) Ratio for Leukemic Transformation in MDS"],"prefix":"10.3390","volume":"18","author":[{"given":"Panagiotis","family":"Panagiotidis","sequence":"first","affiliation":[{"name":"Oncology\/Hematology Clinic, 424 General Military Hospital (424 GMHT), 56429 Thessaloniki, Greece"},{"name":"Biomedical Sciences Unit, Faculty of Health Sciences, Metropolitan College, Campus of Thessaloniki, 54626 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Karavanis","sequence":"additional","affiliation":[{"name":"Oncology\/Hematology Clinic, 424 General Military Hospital (424 GMHT), 56429 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Neanidis","sequence":"additional","affiliation":[{"name":"Oncology\/Hematology Clinic, 424 General Military Hospital (424 GMHT), 56429 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-388X","authenticated-orcid":false,"given":"Eleftherios","family":"Panteris","sequence":"additional","affiliation":[{"name":"Biomedical Sciences Unit, Faculty of Health Sciences, Metropolitan College, Campus of Thessaloniki, 54626 Thessaloniki, Greece"},{"name":"Neonatology\/Neonatal Intensive Care Unit (NICU), University General Hospital of Heraklion, University of Crete, 71003 Heraklion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5820-1759","authenticated-orcid":false,"given":"Maria","family":"Moysidou","sequence":"additional","affiliation":[{"name":"Biomedical Sciences Unit, Faculty of Health Sciences, Metropolitan College, Campus of Thessaloniki, 54626 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Balaian, E., Wobus, M., Bornh\u00e4user, M., Chavakis, T., and Sockel, K. (2021). Myelodysplastic Syndromes and Metabolism. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011250"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Yan, L., Fan, C., Zhao, B., Chen, M., Hao, X., Zhu, G., Jia, Y., Xu, Y., and Shi, Z. (2026). Myelodysplastic syndrome progress to acute myeloid leukemia: New insights and updates. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1769944"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/07853890.2015.1009156","article-title":"Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy","volume":"47","author":"Dan","year":"2015","journal-title":"Ann. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.seminhematol.2020.12.003","article-title":"The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia","volume":"58","author":"Chakraborty","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"B\u0103nescu, C., Tripon, F., and Muntean, C. (2023). The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065734"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Choi, H.S., Kim, B.S., Yoon, S., Oh, S.O., and Lee, D. (2024). Leukemic Stem Cells and Hematological Malignancies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126639"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.path.2015.10.004","article-title":"Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"9","author":"Nardi","year":"2016","journal-title":"Surg. Pathol. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101512","DOI":"10.1016\/j.beha.2023.101512","article-title":"Cytogenetics and molecular genetics of myelodysplastic neoplasms","volume":"36","author":"Ning","year":"2023","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Aanei, C.M., Picot, T., Tavernier, E., Guyotat, D., and Campos Catafal, L. (2016). Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Front. Oncol., 6.","DOI":"10.3389\/fonc.2016.00161"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Verigou, E., Chatzilygeroudi, T., Lazaris, V., De Lastic, A.L., and Symeonidis, A. (2024). Immunophenotyping myelodysplastic neoplasms: The role of flow cytometry in the molecular classification era. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1447001"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/onco2030011","article-title":"The Role of Immune Checkpoint Blockade in Acute Myeloid Leukemia","volume":"2","author":"Silva","year":"2022","journal-title":"Onco"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dong, Y., Han, Y., Huang, Y., Jiang, S., Huang, Z., Chen, R., Yu, Z., Yu, K., and Zhang, S. (2020). PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01710"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","article-title":"Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells","volume":"101","author":"Brenchley","year":"2003","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12979-025-00542-8","article-title":"Re-evaluating CD57 as a marker of T cell senescence: Implications for immune ageing and differentiation","volume":"22","author":"Autaa","year":"2025","journal-title":"Immun. Ageing"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/2767-9764.CRC-24-0310","article-title":"Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine","volume":"4","author":"Tasis","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11899-018-0463-9","article-title":"Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes","volume":"13","author":"Ivy","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17128","DOI":"10.1038\/s41598-025-01600-3","article-title":"Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status","volume":"15","author":"Jiao","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Peng, X., Zhu, X., Di, T., Tang, F., Guo, X., Liu, Y., Bai, J., Li, Y., Li, L., and Zhang, L. (2022). The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.994053"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eadg0539","DOI":"10.1126\/sciimmunol.adg0539","article-title":"PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors","volume":"8","author":"Gill","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20406207231183330","DOI":"10.1177\/20406207231183330","article-title":"Immune dysregulation and potential targeted therapy in myelodysplastic syndrome","volume":"14","author":"Zhang","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e004012","DOI":"10.1136\/jitc-2021-004012","article-title":"CD8+ PD-1+ to CD4+ PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers","volume":"10","author":"Duchemann","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/hsr2.90","article-title":"Implementation of the Ogata flow cytometric scoring system in routine diagnostics of myelodysplastic syndrome","volume":"1","author":"Matzen","year":"2018","journal-title":"Health Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/asheducation-2016.1.462","article-title":"Treatment of low-risk myelodysplastic syndromes","volume":"2016","author":"Santini","year":"2016","journal-title":"Hematology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2165\/11202840-000000000-00000","article-title":"Azacitidine: A Review of its Use in Higher-Risk Myelodysplastic Syndromes\/Acute Myeloid Leukaemia","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., and Salaroli, A. (2022). New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073887"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2017.12.013","article-title":"Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies","volume":"122","author":"Wang","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"key":"ref_41","first-page":"300","article-title":"Diagnosis of myelodysplastic syndromes: The classic and the novel","volume":"110","author":"Oster","year":"2024","journal-title":"Haematologica"},{"key":"ref_42","first-page":"103409","article-title":"Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytog\u00e9n\u00e9tiqueh\u00e9matologique (GFCH)","volume":"71","author":"Auger","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1038\/s41375-025-02746-9","article-title":"The evolving nosology of myeloid neoplasms: The semi-centennial of the 1976 French-American-British classification","volume":"39","author":"Patel","year":"2025","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhou, H., Jia, B., Annageldiyev, C., Minagawa, K., Zhao, C., Mineishi, S., Ehmann, W.C., Naik, S.G., Cioccio, J., and Wirk, B. (2023). CD26lowPD-1+ CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1169144"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","article-title":"Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia","volume":"29","author":"Tan","year":"2017","journal-title":"Chin. J. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Xu, L., Liu, L., Yao, D., Zeng, X., Zhang, Y., Lai, J., Zhong, J., Zha, X., Zheng, R., and Lu, Y. (2021). PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.686156"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Li, X., Wang, W., Zhang, X., and Wu, Y. (2022). Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.949534"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.2023023166","article-title":"T-cell dysfunctions in myelodysplastic syndromes","volume":"143","author":"Colla","year":"2024","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12935-023-03137-9","article-title":"Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T\/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Cell Int."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/2\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:44:48Z","timestamp":1776257088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/2\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["hematolrep18020029"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18020029","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}